The association between previous use of anti‐obesity medication and semaglutide weight loss outcomes
Authors' conclusion
The use of semaglutide in patients with previous intake of other AOMs was associated with inferior weight loss outcomes in comparison to patients who were AOM-naïve.
Study context
- Population
- Patients with overweight or obesity taking semaglutide for weight loss for 3 to 12 months
- Participants
- 305 patients
- Exposure
- Anti-obesity medication (AOM)-naïve vs non-AOM-naïve patients starting semaglutide
- AOM-naïven = 231
- non-AOM-naïven = 74reference
- Outcome
- Percentage of total body weight loss (TBWL)
- Follow-up
- 3, 6, 9 and 12 months
Main finding
As reported in the abstract
TBWL (%) · 12 months
P = 0.01 at 12 months
- Total body weight loss (TBWL) at 3 months, AOM-naïve vs non-AOM-naïve
- 6.3% vs. 3.8%
- TBWL at 6 months, AOM-naïve vs non-AOM-naïve
- 10.6% vs. 6.7%
- TBWL at 9 months, AOM-naïve vs non-AOM-naïve
- 14.0% vs. 9.1%
- P at 3, 6 and 9 months
- P < 0.0001
Observational data: associations, not effects.
Secondary outcomes
TBWL ≥15% · 12 months
P = 0.02
TBWL ≥20% · 12 months
P < 0.01
Original publication
The association between previous use of anti‐obesity medication and semaglutide weight loss outcomes. Diabetes Obes Metab. Published 12 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →